Cargando…

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION

Detalles Bibliográficos
Autores principales:	Danylesko, Ivetta, Shem-Tov, Noga, Yerushalmi, Ronit, Jacoby, Elad, Toren, Amos, Itzhaki, Orit, Shouval, Roni, Shimoni, Avichai, Abraham, Avigdor, Nagler, Arnon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428820/ http://dx.doi.org/10.1097/01.HS9.0000968988.43699.64

Ejemplares similares

P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
por: Geva, Mika, et al.
Publicado: (2023)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
por: Magen, Hila, et al.
Publicado: (2023)

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
por: Varda-Bloom, Nira, et al.
Publicado: (2016)

P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Fried, S., et al.
Publicado: (2022)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis
por: Eshel, Adi, et al.
Publicado: (2022)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
por: Beider, Katia, et al.
Publicado: (2022)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Michael, Maria, et al.
Publicado: (2013)

CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34(+) Cell Mobilization
por: Ostrovsky, Olga, et al.
Publicado: (2021)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
por: Garcia-Prieto, Carlos A, et al.
Publicado: (2021)

Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study
por: Shouval, Roni, et al.
Publicado: (2016)

Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease
por: Shouval, Roni, et al.
Publicado: (2019)

Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease
por: Beider, Katia, et al.
Publicado: (2017)

Impact of cryopreservation on CAR T production and clinical response
por: Brezinger-Dayan, Karin, et al.
Publicado: (2022)

Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death
por: Josefsberg Ben-Yehoshua, Liat, et al.
Publicado: (2012)

CLUSTER OF DIFFERENTIATION (CD) ANTIGENS
Publicado: (2004)

Hsa-miR-520d Converts Fibroblasts into CD105+ Populations
por: Ishihara, Yoshitaka, et al.
Publicado: (2014)

Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies
por: Ostrovsky, Olga, et al.
Publicado: (2018)

The HPSE Gene Insulator—A Novel Regulatory Element That Affects Heparanase Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease
por: Ostrovsky, Olga, et al.
Publicado: (2021)

Comprehensive definition of human immunodominant CD8 antigens in tuberculosis
por: Lewinsohn, Deborah A., et al.
Publicado: (2017)

Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
por: Gross, Golda, et al.
Publicado: (2023)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Human CD3+ T lymphocytes that express neither CD4 nor CD8 antigens
Publicado: (1986)

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Miller, Liron, et al.
Publicado: (2023)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

Activation of CD8(+) T Cell Responses after Melanoma Antigen Targeting to CD169(+) Antigen Presenting Cells in Mice and Humans
por: van Dinther, Dieke, et al.
Publicado: (2019)

Antigen-dependent Proliferation of CD4(+) CD25(+) Regulatory T Cells In Vivo
por: Walker, Lucy S.K., et al.
Publicado: (2003)

An intermediate cell in thymocyte differentiation that expresses CD8 but not CD4 antigen
Publicado: (1987)

Evaluation of the clinical impact of bone marrow cultures in current medical practice
por: Sharvit, Gal, et al.
Publicado: (2022)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
por: Beider, Katia, et al.
Publicado: (2022)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells
por: Nishikawa, Hiroyoshi, et al.
Publicado: (2005)

Similarities in sequences and cellular expression between rat CD2 and CD4 antigens
Publicado: (1987)

Quantitative Contribution of CD4 and CD8 to T Cell Antigen Receptor Serial Triggering
por: Viola, Antonella, et al.
Publicado: (1997)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

Species heterogeneity in macrophage expression of the CD4 antigen
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_cj2f0ttmna3dfsdia1mpsdm0tg